ArticleImmunity, inflammation and disease2026
ASGR1 Deficiency Promotes Liver Fibrosis by Enhancing Pro-Inflammatory Arachidonic Acid Metabolism and ALP Secretion.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Re: ASGR1 Deficiency Promotes Liver Fibrosis by Enhancing Pro-Inflammatory Arachidonic Acid Metabolism and ALP Secretion.Immunity, inflammation and disease · 2026Article
- ASGR1 Deficiency Promotes Liver Fibrosis by Enhancing Pro-Inflammatory Arachidonic Acid Metabolism and ALP Secretion.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAsialoglycoprotein receptor 1 (ASGR1), a hepatocyte-specific receptor, represents a potential therapeutic target for hypercholesterolemia. However, liver safety risks of ASGR1-targeted therapies remain poorly characterized. This study aims to investigate the impact of ASGR1 deficency on liver fibrosis and its underlying mechanisms.
methodsASGR1 knockout (ASGR1
resultsASGR1 deficiency significantly exacerbates liver fibrosis in both CCl
conclusionsASGR1 deficiency aggravates liver fibrosis, which is likely mediated through the "ASGR1-arachidonic acid-ALP" axis that enhances pro-inflammatory eicosanoid production and ALP secretion. These findings highlight the liver-specific safety risk of ASGR1 as a therapeutic target for lipid disorders and provide mechanistic and translational references for clinical safety monitoring of ASGR1-targeted drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.